Dr. Reed’s research interests have focused on the immunology of intracellular infections, and on the development of vaccines and diagnostics for both cancer and infectious diseases. In partnership with GSK, he led the team that developed the first defined tuberculosis vaccine to advance to clinical trials. He also developed the first defined vaccines for leishmaniasis, as well as the K39-based diagnostic tests currently licensed for leishmaniasis. He has more than 375 original publications, 35 book chapters and reviews, and 105 issued patents on diagnostics, vaccines, and therapeutics of infectious diseases and cancer.